A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The three tumour streams that will be studied in this protocol are: (i) upper GI malignancies
(comprising intra-hepatic/extra-hepatic cholangiocarcinomas,gall bladder cancers and duodenal
cancers).); (ii) neuroendocrine tumours (inc. Pancreatic, bronchial and intestinal carcinoid
tumours) and (iii) rare gynaecological tumours (including but will not be limited to: vaginal
or vulval carcinomas, clear cell carcinoma of the ovary, low grade serous ovarian cancer,
mixed mullarian tumours (carcinosarcoma), sarcomas of the female genital tract and granulosa
cell tumours).
The role of immunotherapy is being defined in more common cancer types, however because of
their rarity, the efficacy of immunotherapy for these cancers is poorly defined.
This protocol provides an important opportunity to establish whether the combination of
nivolumab & ipilimumab has efficacy in these cancers.